Skip to main content
KISQALI (ribociclib) tablets box

How is KISQALI dosed in early breast cancer?

For patients with stage II/III hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (eBC) at high risk of recurrence, the starting dose for KISQALI® (ribociclib) is 400 mg (two 200-mg tablets) orally, once daily (3 weeks on, 1 week off), for 3 years, in combination with an aromatase inhibitor (AI). Learn about KISQALI dosing for eBC below.1

In stage II/III HR+/HER2- eBC,

The KISQALI 400-mg once-daily starting dose was chosen to reduce both the risk of recurrence and dose-dependent adverse reactions

(28-day cycle)1

Week 1

Week 2

Week 3

Week 4

Subsequent cycles

KISQALI: 2 
tablets (2 x 200 mg)

checkmark
checkmark
checkmark
orange-dash

Repeat 28-day cycle

AI

gray-checkmark
gray-checkmark
gray-checkmark
gray-checkmark

KISQALI is given as 400 mg (two 200-mg tablets) orally, once daily (3 weeks on, 1 week off) for 3 years with an AI1

  • Review the full Prescribing Information for recommended dosing of selected AI 

  • An LHRH agonist should be used concomitantly with AI in men and premenopausal women

  • Patients should continue treatment for 3 years or until disease recurrence or unacceptable toxicity

  • KISQALI can be taken with or without food

  • Patients may store at room temperature at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F)

  • Store in the original blister package in order to protect from moisture

Starting dose modification for severe renal impairment1

  • The recommended starting dose is 200 mg once daily for patients with severe renal impairment

AI, aromatase inhibitor; eBC, early breast cancer; HER2-, human epidermal growth factor receptor 2-negative; HR+, hormone receptor-positive; LHRH, luteinizing hormone-releasing hormone.

KISQALI Treatment Guide

KISQALI Treatment Guide

A comprehensive guide to treatment with KISQALI + AI that includes dedicated sections to support you in treating your patients with early (stage II or III at high risk of recurrence) or metastatic HR+/HER2- breast cancer.
Download
Reference: 1. Kisqali. Prescribing information. Novartis Pharmaceuticals Corp.